Lexaria Gains IRB Approval for Human Pilot Study #7, Advancing Oral GLP-1 Delivery
LEXX sits 20% above its 52-week low of $0.46 on light trading volume (0.3× avg).
Summary
Lexaria Bioscience Corp. has received Independent Review Board (IRB) approval to commence Human Pilot Study #7 (GLP-1-H26-7). This study is crucial as it will evaluate Lexaria's oral DehydraTECH-semaglutide compositions against Novo Nordisk's commercially available Wegovy® tablets, aiming for superior safety and tolerability with comparable or improved pharmacokinetic performance over a five-week period. This development is particularly significant for Lexaria, which has previously reported substantial doubt about its ability to continue as a going concern and received a Nasdaq delisting warning, as it represents a material step forward in validating its core technology and attracting potential commercial partners. The study will introduce novel tablet formulations and multi-dose SNAC evaluation, with dosing expected to begin in mid-June. Positive outcomes could significantly de-risk the DehydraTECH platform for GLP-1 drugs and provide a much-needed catalyst for the company.
At the time of this announcement, LEXX was trading at $0.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.9M. The 52-week trading range was $0.46 to $1.55. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Access Newswire.